Skip to main content

Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases.

Jung K

Publication: Clin Chem Lab Med (2006) • Vol 44 • Page 500-2PMID: 16599848View on PubMed

Purpose

The purpose of this paper was to determine the effects of anticoagulant type, presence of clot activator in the serum collection tube, and the analysis of serum versus plasma on matrix metalloproteinase 9 (MMP-9) concentrations in healthy individuals and those with renal cell carcinoma (RCC).

Conclusion

MMP-9 concentrations were 10 to 20-fold higher in serum, collected with or without clot activator, than in plasma, regardless of which anticoagulant was used during collection. Serum collected with clot activator had significantly higher concentrations of MMP-9 than serum collected without clot activator. The authors state that strong correlations were observed between MMP-9 concentrations in heparin, citrate, and EDTA plasma. When specimens from healthy individuals were compared with those from RCC patients, higher concentrations of MMP-9 were seen in heparin plasma from RCC patients than in heparin plasma from healthy individuals, but there was no significant difference in serum MMP-9 concentrations.

Studies (1)

Purpose

The purpose of this study was to determine the effects of anticoagulant type, presence of clot activator in the serum collection tube, and the analysis of serum versus plasma on MMP-9 concentrations in healthy individuals and those with RCC. Serum and plasma were prepared within 30 minutes of blood collection and were stored at -80 degrees C until analysis.

Summary of Findings

MMP-9 concentrations were 10 to 20-fold higher in serum, collected with or without clot activator, than in plasma, regardless of which anticoagulant was used during collection. Serum collected with clot activator had significantly higher concentrations of MMP-9 than serum collected without clot activator. The authors state that strong correlations were observed between MMP-9 concentrations in heparin, citrate, and EDTA plasma. When specimens from healthy individuals were compared with those from RCC patients, higher concentrations of MMP-9 were seen in heparin plasma from RCC patients than in heparin plasma from healthy individuals (p<0.0001), but there was no significant difference in serum MMP-9 concentrations.

  • Biospecimens

    FluidPlasma
    FluidSerum
    FluidBlood
  • Preservation Types

    Frozen
  • Diagnoses

    Normal
    NeoplasticCarcinoma
  • Platforms

    ProteinELISA
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Normal
    Renal cell carcinoma
    Biospecimen AcquisitionAnticoagulant
    Lithium heparin
    Potassium EDTA
    Sodium citrate
    Biospecimen AcquisitionType of collection container/solution
    Tube with clot activator
    Tube with no clot activator
    Biospecimen Aliquots and ComponentsBlood and blood products
    Plasma
    Serum